Agennix AG i.L.
GPC Biotech AG english
GPC Biotech to Present at UBS Global Life Sciences Conference in New York
Corporate-news announcement sent by DGAP.
The sender is solely responsible for the contents of this announcement.
——————————————————————————–
GPC Biotech to Present at UBS Global Life Sciences Conference in New York
Martinsried/Munich (Germany) and U.S. Research Facilities in Waltham/Boston,
Mass. and Princeton, N.J., September 18, 2003 – GPC Biotech AG (Frankfurt Stock
Exchange: GPC; TecDAX 30) today announced that the Company will be presenting
at the UBS Global Life Sciences Conference for investors. The presentation will
be given by Dr. Mirko Scherer, Senior Vice President and Chief Financial Officer
of the Company, and is scheduled to begin at 1:30 PM EDT on Tuesday, September
23, 2003 at The Plaza hotel in New York City. The presentation will be webcast
live and can be accessed through the GPC Biotech Web site at
http://www.gpc-biotech.com . A replay will be available via the Web site 24
hours after the live presentation.
GPC Biotech AG is a biotechnology company dedicated to discovering and
developing new anticancer drugs through innovative discovery technologies and
development approaches. The Company’s lead product candidate – satraplatin –
has successfully completed the Special Protocol Assessment (SPA) process with
the U.S. FDA and is expected to enter a Phase 3 registrational study in the near
future. The Company is leveraging its drug discovery technologies in novel ways
to elucidate the mechanisms-of-action of drug candidates and to support the
growth of its drug pipeline. The Company has formed successful collaborations
with a number of pharmaceutical firms, including ALTANA Pharma of ALTANA AG
(FSE: ALT; NYSE: AAA), Aventis Pharma (PAVE.PSE), Bayer AG (FSE: BAY; NYSE:
BAY), Boehringer Ingelheim International GmbH, Eli Lilly and Company (NYSE: LLY)
and Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI). GPC Biotech AG is
headquartered in Martinsried/Munich (Germany). The Company’s wholly owned U.S.
subsidiary has research sites in Waltham, Massachusetts and Princeton, New
Jersey. For additional information, please visit the Company’s Web site at
http://www.gpc-biotech.com .
The economic projections and forward-looking statements contained in this
document relate to future facts. Such projections and forward-looking statements
are subject to risks which cannot be foreseen and which are beyond the control
of GPC Biotech AG. GPC Biotech AG is therefore not in a position to make any
representation as to the accuracy of economic projections and forward-looking
statements or their impact on the financial situation of GPC Biotech AG or the
market in the shares of GPC Biotech AG.
For further information, please contact:
GPC Biotech AG, Fraunhoferstr. 20, 82152 Martinsried/Munich, Germany
Phone/Fax: +49 (0)89 8565-2600/-2610, info@gpc-biotech.com
Martin Braendle (ext. 2693), Manager, Investor Relations & Corporate
Communications
martin.braendle@gpc-biotech.com
In the U.S.:
Laurie Doyle, Sr. Manager, Investor Relations & Corporate Communications
Phone: +1 781 890 9007 X267, laurie.doyle@gpc-biotech.com
Additional Media Contacts:
Euro RSCG Life NRP
In NY: Mark Vincent, Vice President, Phone: +1 212 845 4239,
mark.vincent@eurorscg.com
In London: Veronica Sellar, Senior Account Manager, Tel.: +44 20 7726 4452,
veronica.sellar@eurorscg.com
end of message, (c)DGAP 18.09.2003
——————————————————————————–
WKN: 585150; ISIN: DE0005851505; Index: TecDAX, NEMAX 50
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-
Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart
181600 Sep 03
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden